p.77 抽出テキスト

239. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146: 857–67. https://doi.org/10.7326/0003-4819-146-12-200706190-00007 240. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383: 955–62. https://doi.org/10.1016/S0140-6736(13)62343-0 241. Sjalander S, Sjalander A, Svensson PJ, Friberg L. Atrial fibrillation patients do not benefit from acetylsalicylic acid. Europace 2014;16:631–8. https://doi.org/10.1093/europace/ eut333 242. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806–17. https://doi.org/10.1056/ NEJMoa1007432 243. van Doorn S, Rutten FH, O’Flynn CM, Oudega R, Hoes AW, Moons KGM, et al. Effectiveness of CHA2DS2-VASc based decision support on stroke prevention in atrial fibrillation: a cluster randomised trial in general practice. Int J Cardiol 2018;273:123–9. https://doi.org/10.1016/j.ijcard.2018.08.096 244. Borre ED, Goode A, Raitz G, Shah B, Lowenstern A, Chatterjee R, et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost 2018;118:2171–87. https://doi.org/10.1055/s- 0038-1675400 245. van der Endt VHW, Milders J, de Vries BBLP, Trines SA, Groenwold RHH, Dekkers OM, et al. Comprehensive comparison of stroke risk score performance: a systematic review and meta-analysis among 6 267 728 patients with atrial fibrillation. Europace 2022;24:1739–53. https://doi.org/10.1093/europace/euac096 246. Quinn GR, Severdija ON, Chang Y, Singer DE. Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation. Circulation 2017;135: 208–19. https://doi.org/10.1161/CIRCULATIONAHA.116.024057 247. Pisters R, Lane DA, Marin F, Camm AJ, Lip GY. Stroke and thromboembolism in atrial fibrillation. Circ J 2012;76:2289–304. https://doi.org/10.1253/circj.CJ-12-1036 248. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012;33:2821–30. https://doi.org/10.1093/eurheartj/ehs274 249. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32:2387–94. https://doi.org/10.1093/eurheartj/ehr342 250. Yaghi S, Henninger N, Giles JA, Leon Guerrero C, Mistry E, Liberman AL, et al. Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke: the IAC study. J Neurol Neurosurg Psychiatry 2021;92:1062–7. https://doi. org/10.1136/jnnp-2021-326166 251. Ocak G, Khairoun M, Khairoun O, Bos WJW, Fu EL, Cramer MJ, et al. Chronic kidney disease and atrial fibrillation: a dangerous combination. PLoS One 2022;17:e0266046. https://doi.org/10.1371/journal.pone.0266046 252. Seiffge DJ, De Marchis GM, Koga M, Paciaroni M, Wilson D, Cappellari M, et al. Ischemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation. Ann Neurol 2020;87:677–87. https://doi.org/10.1002/ana.25700 253. Paciaroni M, Agnelli G, Falocci N, Caso V, Becattini C, Marcheselli S, et al. Prognostic value of trans-thoracic echocardiography in patients with acute stroke and atrial fibrillation: findings from the RAF study. J Neurol 2016;263:231–7. https://doi.org/10.1007/ s00415-015-7957-3 254. Hijazi Z, Oldgren J, Siegbahn A, Wallentin L. Application of biomarkers for risk stratification in patients with atrial fibrillation. Clin Chem 2017;63:152–64. https://doi.org/10. 1373/clinchem.2016.255182 255. Singleton MJ, Yuan Y, Dawood FZ, Howard G, Judd SE, Zakai NA, et al. Multiple blood biomarkers and stroke risk in atrial fibrillation: the REGARDS study. J Am Heart Assoc 2021;10:e020157. https://doi.org/10.1161/JAHA.120.020157 256. Wu VC, Wu M, Aboyans V, Chang SH, Chen SW, Chen MC, et al. Female sex as a risk factor for ischaemic stroke varies with age in patients with atrial fibrillation. Heart 2020; 106:534–40. https://doi.org/10.1136/heartjnl-2019-315065 257. Mikkelsen AP, Lindhardsen J, Lip GY, Gislason GH, Torp-Pedersen C, Olesen JB. Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. J Thromb Haemost 2012;10:1745–51. https://doi.org/10.1111/j.1538-7836.2012. 04853.x 258. Antonenko K, Paciaroni M, Agnelli G, Falocci N, Becattini C, Marcheselli S, et al. Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: results from the RAF study (early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation). Eur Stroke J 2017;2:46–53. https://doi.org/10.1177/2396987316679577 259. Wang X, Mobley AR, Tica O, Okoth K, Ghosh RE, Myles P, et al. Systematic approach to outcome assessment from coded electronic healthcare records in the DaRe2THINK NHS-embedded randomized trial. Eur Heart J - Dig Health 2022;3: 426–36. https://doi.org/10.1093/ehjdh/ztac046 260. Rivard L, Khairy P, Talajic M, Tardif JC, Nattel S, Bherer L, et al. Blinded randomized trial of anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation (BRAIN-AF): methods and design. Can J Cardiol 2019;35:1069–77. https:// doi.org/10.1016/j.cjca.2019.04.022 261. Chung S, Kim TH, Uhm JS, Cha MJ, Lee JM, Park J, et al. Stroke and systemic embolism and other adverse outcomes of heart failure with preserved and reduced ejection fraction in patients with atrial fibrillation (from the COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation [CODE-AF]). Am J Cardiol 2020;125:68–75. https://doi.org/10.1016/j.amjcard.2019.09.035 262. Uhm JS, Kim J, Yu HT, Kim TH, Lee SR, Cha MJ, et al. Stroke and systemic embolism in patients with atrial fibrillation and heart failure according to heart failure type. ESC Heart Fail 2021;8:1582–9. https://doi.org/10.1002/ehf2.13264 263. McMurray JJ, Ezekowitz JA, Lewis BS, Gersh BJ, van Diepen S, Amerena J, et al. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail 2013;6:451–60. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000143 264. Kim D, Yang PS, Kim TH, Jang E, Shin H, Kim HY, et al. Ideal blood pressure in patients with atrial fibrillation. J Am Coll Cardiol 2018;72:1233–45. https://doi.org/10.1016/j.jacc. 2018.05.076 265. Lip GY, Clementy N, Pericart L, Banerjee A, Fauchier L. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire valley atrial fibrillation project. Stroke 2015;46:143–50. https://doi.org/10.1161/STROKEAHA.114. 007199 266. American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2022. Diabetes Care 2022; 45:S17–38. https://doi.org/10.2337/dc22-S002 267. Steensig K, Olesen KKW, Thim T, Nielsen JC, Jensen SE, Jensen LO, et al. Should the presence or extent of coronary artery disease be quantified in the CHA2DS2-VASc score in atrial fibrillation? A report from the western Denmark heart registry. Thromb Haemost 2018;118:2162–70. https://doi.org/10.1055/s-0038-1675401 268. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke prevention in atrial fibrillation III investigators. J Am Coll Cardiol 1998;31:1622–6. https://doi.org/10.1016/S0735-1097(98)00146-6 269. Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiography in atrial fibrillation: standards for acquisition and interpretation and assessment of interobserver variability. Stroke prevention in atrial fibrillation investigators committee on echocardiography. J Am Soc Echocardiogr 1996; 9:556–66. https://doi.org/10.1016/S0894-7317(96)90127-3 270. Lozier MR, Sanchez AM, Lee JJ, Donath EM, Font VE, Escolar E. Thromboembolic outcomes of different anticoagulation strategies for patients with atrial fibrillation in the setting of hypertrophic cardiomyopathy: a systematic review. J Atr Fibrillation 2019; 12:2207. https://doi.org/10.4022/jafib.2207 271. Guttmann OP, Rahman MS, O’Mahony C, Anastasakis A, Elliott PM. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart 2014;100:465–72. https://doi.org/10.1136/heartjnl-2013-304276 272. Guttmann OP, Pavlou M, O’Mahony C, Monserrat L, Anastasakis A, Rapezzi C, et al. Prediction of thromboembolic risk in patients with hypertrophic cardiomyopathy (HCM risk-CVA). Eur J Heart Fail 2015;17:837–45. https://doi.org/10.1002/ejhf.316 273. Vilches S, Fontana M, Gonzalez-Lopez E, Mitrani L, Saturi G, Renju M, et al. Systemic embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail 2022;24: 1387–96. https://doi.org/10.1002/ejhf.2566 274. Lee SE, Park JK, Uhm JS, Kim JY, Pak HN, Lee MH, et al. Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy. Heart 2017;103:1496–501. https://doi.org/10.1136/heartjnl-2016-310720 275. Hirota T, Kubo T, Baba Y, Ochi Y, Takahashi A, Yamasaki N, et al. Clinical profile of thromboembolic events in patients with hypertrophic cardiomyopathy in a regional Japanese cohort–results from Kochi RYOMA study. Circ J 2019;83:1747–54. https:// doi.org/10.1253/circj.CJ-19-0186 276. Hsu JC, Huang YT, Lin LY. Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study. Aging (Albany NY) 2020;12:24219–27. https://doi.org/10.18632/aging.104133 277. Chao TF, Lip GYH, Liu CJ, Lin YJ, Chang SL, Lo LW, et al. Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation. J Am Coll Cardiol 2018;71:122–32. https://doi.org/10.1016/j.jacc.2017.10.085 278. Weijs B, Dudink E, de Vos CB, Limantoro I, Tieleman RG, Pisters R, et al. Idiopathic atrial fibrillation patients rapidly outgrow their low thromboembolic risk: a 10-year follow-up study. Neth Heart J 2019;27:487–97. https://doi.org/10.1007/s12471-019- 1272-z 279. Bezabhe WM, Bereznicki LR, Radford J, Wimmer BC, Salahudeen MS, Garrahy E, et al. Stroke risk reassessment and oral anticoagulant initiation in primary care patients with atrial fibrillation: A ten-year follow-up. Eur J Clin Invest 2021;51:e13489. https://doi.org/ 10.1111/eci.13489 280. Fauchier L, Bodin A, Bisson A, Herbert J, Spiesser P, Clementy N, et al. Incident comorbidities, aging and the risk of stroke in 608,108 patients with atrial fibrillation: a nationwide analysis. J Clin Med 2020;9:1234. https://doi.org/10.3390/jcm9041234 Downloaded from academic.oup.com/eurheartj/article/45/36/3314/7738779 by guest on 07 October 2026